SCHEDULE: Vanguard Group Reports 0% Stake in Castle Biosciences

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Castle Biosciences Inc. due to an internal corporate realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 3 to its Schedule 13G regarding its holdings in Castle Biosciences Inc.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of the class of Common Stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral for Castle Biosciences. The change in reported ownership by The Vanguard Group is due to an internal corporate realignment for reporting purposes and does not indicate a change in investment strategy or a sale of shares by Vanguard's managed funds.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Castle Biosciences Inc.'s future performance or operations.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock, primarily for passive investment purposes. This amendment reflects an internal organizational change within The Vanguard Group, rather than a divestment of shares by Vanguard's overall managed funds. The disaggregated reporting means that while The Vanguard Group, Inc. itself reports 0% beneficial ownership, its various subsidiaries and managed funds may still collectively hold significant stakes in Castle Biosciences, which will now be reported individually by those entities.

Stakeholder Impact

• Shareholders: Minimal direct impact, as the change reflects an internal reporting adjustment by Vanguard rather than a change in the underlying investment by Vanguard's managed funds. Individual Vanguard funds may still hold shares.

Key Dates

Keywords

Castle Biosciences, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Common Stock, Corporate Realignment